Pharma
Bristol-Myers Squibb Co.: PharmaVitae Profile
This analysis examines the historical and forecast performance for BMS
in the prescription pharmaceutical sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and assessment
of financial performance, with 1-6 year sales forecasts for key drugs.
Sept 2009
AstraZeneca plc: PharmaVitae Profile
This analysis examines the historical and forecast performance for
AstraZeneca in the Rx pharmaceutical sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and assessment
of financial performance, with 1-6 year sales forecasts for key drugs.
Sept 2009
Abbott Laboratories: PharmaVitae Profile
This analysis examines the historical and forecast performance for
Abbott in the prescription pharmaceutical sector. The profile
encompasses global company strategy, portfolio and pipeline analysis and
assessment of financial performance, with 1-6 year sales forecasts for
key drugs. Sept 2009
British
National Formulary
Medicines prescribed in the UK, with special reference to their uses,
cautions, contra-indications, side-effects, doses and relative costs.
read more ...
Diabetes Drug
Pipeline. Competitor Analysis
The Competitive Intelligence Report Diabetes Drug Pipeline as of
November 2008 provides a competitor analysis in the development pipeline
of novel antidiabetic treatment modalities for type 1 and 2 diabetes.
The report includes an overview of the major marketed diabetes drugs and
the respective markets sizes and describes the corporate diabetes drug
product portfolios and R&D pipelines of more than 160 companies
worldwide. November 2008
Biopharmaceutical Expression Systems and Genetic Engineering
Technologies. Current and Future Manufacturing Platforms
In currently marketed products there has been little basic change in the
technologies used for commercial-scale manufacture of biopharmaceutical
products. New expression systems and recent improvements available for current
systems have the potential to revolutionize the biopharmaceutical industry! Lower
costs and efficiencies of newer expression systems are driving these
changes. This book provides manufacturers with the information they need
to make the shift to increased productivity. November 2008
Why do drugs fail?
This report analyses recent drug failure events and examines
potential areas of remedy for regulators and companies. Greedy companies
being economical with the truth?
Overzealous regulators pursuing political agendas? Poorly designed or
inconclusive clinical trials? What action can the industry and
regulators take to improve their performance in this critical area?
November 2008
Global Surgical Equipment Investment Opportunities, Analysis and
Forecasts to 2012
This report is an essential source for key information and data
relating to the Global surgical equipment market. The report provides
overview of key trends, drivers and restraints, future outlook, pipeline
products, news, financial deals and competitive landscape and key
developments in the Global surgical equipment devices market. It also
offers global and country level, detailed and comprehensive coverage of
market revenue, volume, distribution and company share information.
October 2008
Top 20
cancer therapy brands
Cancer therapy brand sales totaled over $30 billion in the seven major
markets in 2007, growing by 20.1% since 2006. The high growth of this
market makes it attractive to companies keen to emulate the blockbuster
status achieved by several brands. However, with several impending
patent expiries due, companies will need to work hard to maximize their
return throughout the lifecycle of their brands. 9 September 2008
Antidiabetics — Switching to new antidiabetics drives market growth
Datamonitor expects the antidiabetics market in the seven major markets is expected to
grow from $18 billion in 2007 to $29 billion in 2017 at a rate of 5%
CAGR. Significant unmet needs remain in diabetes fuelling a large
pipeline. The epidemiological growth of the market, driven by the
obesity epidemic and improved diagnosis rates, is further driving the
market. 9 September 2008
To top
|